Leap Therapeutics stock jumps 47% on positive DKN-01 + tislelizumab data in gastroesophageal cancer

Leap Therapeutics stock jumps 47% on positive DKN-01 + tislelizumab data in gastroesophageal cancer
Source link
Leap Therapeutics stock jumps 47% on positive DKN-01 + tislelizumab data in gastroesophageal cancer
Source link